Last reviewed: June 26, 2026
Last updated: June 26, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Wegovy (semaglutide) and Zepbound (tirzepatide) are both FDA-approved weight loss medications, but they work through different biological pathways. Clinical trials show tirzepatide produces approximately 20-22% weight loss compared to semaglutide's 15-18% average reduction. Choosing between them depends on your metabolic profile, response potential, and treatment goals.
How Wegovy and Zepbound Work Differently in Your Body
Wegovy contains semaglutide, a GLP-1 receptor agonist that signals your brain to feel fuller longer and reduces hunger hormones. Zepbound uses tirzepatide, which activates both GLP-1 and GIP receptors simultaneously, creating a dual hormonal effect. This dual-pathway mechanism gives tirzepatide a distinct advantage in suppressing appetite and regulating blood sugar compared to single-pathway GLP-1 therapy.
Your body's genetic predispositions influence how effectively each medication works for you. The GLP1R gene variant (rs6923761) and GIPR gene variant (rs1800437) determine receptor sensitivity and response potential to these treatments. PlexusDx's Precision Peptide Genetic Test maps these variants across 14 metabolic pathways, helping identify whether you're genetically optimized for GLP-1 monotherapy or dual-agonist treatment.
Clinical Weight Loss Results: Wegovy vs Zepbound Efficacy
The STEP clinical trials demonstrated that semaglutide (Wegovy) achieves average weight loss of 15-18% of body weight over 68 weeks at maximum doses. The SUMO trials showed tirzepatide (Zepbound) produced 20-22% weight loss at comparable timeframes, with some participants achieving reductions exceeding 25%. These data indicate tirzepatide's dual-receptor activation generates meaningfully superior outcomes for most patients.
Blood sugar control also differs between the two medications. Tirzepatide improves HbA1c levels more substantially than semaglutide, making it advantageous if you have prediabetes or metabolic syndrome alongside weight management goals. Semaglutide remains highly effective for patients without glucose dysregulation or those seeking a single-mechanism approach.
Side Effects and Tolerability: What to Expect
Both medications commonly cause nausea, vomiting, diarrhea, and constipation during dose escalation, though these effects typically diminish after 2-4 weeks of adaptation. Tirzepatide may produce slightly more gastrointestinal side effects initially due to its dual-pathway activation, but serious adverse events remain rare in clinical populations. Individual tolerability depends on genetic factors affecting GI motility and receptor sensitivity.
Pancreatitis, thyroid concerns, and gallbladder complications remain uncommon but warrant monitoring with either medication. Patients with personal or family history of medullary thyroid cancer should avoid both options. Discussing your complete medical history with a PlexusDx clinician ensures safe medication selection based on your individual risk profile.
Cost, Access, and Personalized Treatment at PlexusDx
PlexusDx offers compounded tirzepatide injection starting at $249/month through licensed 503A pharmacies, with no insurance requirement or membership fees. Oral tirzepatide is available at $279/month for patients preferring non-injection therapy. Both options are HSA/FSA eligible, making precision weight loss therapy accessible regardless of insurance coverage.
The Precision Peptide Genetic Test ($99 add-on after first month) analyzes your FTO, MC4R, GIPR, and GLP1R variants to predict treatment responsiveness and personalize your compound selection. Patients with favorable tirzepatide-pathway genetics often see superior results compared to those genetically optimized for semaglutide. This precision approach eliminates trial-and-error medication selection and accelerates your path to sustained weight loss.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is tirzepatide always better than semaglutide for weight loss?
While tirzepatide produces statistically superior average weight loss (20-22% vs 15-18%), individual response varies based on genetic factors and metabolic profile. The Precision Peptide Genetic Test identifies your pathway-specific predispositions, revealing whether you're genetically optimized for dual-agonist or single-receptor therapy. PlexusDx clinicians use this data to recommend the most effective compound for your unique biology.
How long does it take to see weight loss results with either medication?
Most patients notice appetite suppression within 5-7 days of starting treatment. Measurable weight loss typically appears within 2-4 weeks as your body adapts to reduced caloric intake. Maximum clinical benefit develops over 16-20 weeks as doses escalate to therapeutic levels, with sustained results continuing through 12+ months of consistent treatment.
Can I switch from Wegovy to Zepbound if I'm not seeing results?
Yes, switching between medications is safe and often beneficial if you plateau on one therapy. PlexusDx supports flexible treatment adjustments based on your progress and genetic predispositions. If your Precision Peptide Genetic Test suggests tirzepatide optimization, transitioning from semaglutide to PlexusDx's compounded tirzepatide injection ($249/month) often unlocks superior results without flat per-compound pricing increases.
What genetic factors make someone a better candidate for tirzepatide?
Favorable GIPR rs1800437 and GLP1R rs6923761 variants indicate enhanced dual-receptor sensitivity, predicting stronger response to tirzepatide's combination mechanism. FTO rs9939609 and MC4R rs17782313 variants also influence satiety signaling and metabolic efficiency. PlexusDx maps all four markers across 14 pathways to identify your personalized compound match with 150+ genetic insights.
Why is PlexusDx compounded tirzepatide more affordable than brand-name Zepbound?
PlexusDx sources from licensed 503A compounding pharmacies, which produce medications at lower cost than brand manufacturers while maintaining rigorous quality standards. The flat $249/month pricing means your dose can increase as needed without price changes. HSA/FSA eligibility further reduces out-of-pocket expenses compared to retail Zepbound.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Where Does the Ozempic Shot Go? A Guide to Injection Sites
What Percentage of Weight Do You Lose on Ozempic?